Tag: Marketwatch

Apr 23
Gold futures end lower for the session and week

Gold futures fell Friday, down a fourth straight session, to post a loss of 2.1% for the week, according to Dow Jones Market Data. Prices fell “agonisingly short of $2,000 an ounce earlier this week, before slipping back,” said Michael Hewson, chief market analyst at CMC Markets UK. They finished the week lower, as another […]

Apr 23
Oil futures post a loss for the week on demand concerns

Oil futures settled lower on Friday, contributing to a loss for the week. Market bears are concerned that “oil demand may not persist amidst the cloudy macro-economic environment,” said Manish Raj, chief financial officer at Velandera Energy Partners. “On the one hand we have [a] potential GDP slowdown due to rising interest rates and on […]

Apr 23
Dow skids nearly 900 points Friday as stock selloff accelerates

Powell spoke on Thursday, not Wednesday. This article has been corrected. Stocks fell sharply Friday afternoon, with the Dow down nearly 900 points as losses on Wall Street intensified ahead of the weekend. The Dow industrials skid 886 points, or 2.5%, to about 33,909, heading for its worst daily percent decline since Nov. 26, 2021, […]

Apr 23
2-year Treasury yield rises to nearly 2.72%, adding to its highest level since December 2018

The 2-year Treasury yield TMUBMUSD02Y, 2.721% advanced two basis points to almost 2.72% on Friday, incrementally climbing to another fresh high last seen in December of 2018, according to FactSet data as of 3 p.m. Eastern time. The rate climbed around 28 basis points for the week as traders began to price in the likely […]

Apr 22
Stocks sharply lower, but trim losses as Fed’s Mester pours cold water on 75 basis point hike

U.S. stocks remained on track for the biggest one-day drop since early March, but came off session lows after Cleveland Federal Reserve Bank President Loretta Mester said she didn’t see a need for a 75 basis point rate hike. In a CNBC interview, Mester said she would prefer a “methodical approach” rather than the “shock” […]

Apr 22
Dow closes down 981 points Friday, books worst day since October 2020

Stocks finish sharply lower Friday to book weekly losses, as Wall Street focused on a potentially compressed timeline for the Federal Reserve to swiftly raise interest rates in a bid to curtail inflation at 1980s levels. The Dow Jones Industrial Average DJIA, -2.82% shed about 981 points, or 2.8%, ending near 33,811. It marked the […]

Apr 22
Only 30 S&P 500 stocks are gaining, as health care stocks lead the losers

With the S&P 500 SPX, -2.53% tumbling 2.2%, toward the biggest one-day selloff in about seven weeks, only 30 of the index’s components are trading higher. The biggest gainer is SVB Financial Group’s stock SIVB, +8.85%, which rallied 10.7% after the banking company reported late Thursday first-quarter profit and revenue that beat expectations. The next […]

Apr 22
Dow’s stock heads for record win streak, is the lone gainer among Dow industrials members

Shares of Dow Inc. DOW, -0.03% rose 0.4% in midday trading, which puts them on track to extend their winning streak to the longest on record. The stock specialty chemical company’s stock is also the lone gainer among components of the Dow Jones Industrial Average DJIA, -1.68%, which tumbled 514 points, or 1.5%. Dow’s stock, […]

Apr 22
LME to end gold and silver futures trading by July: reports

The London Metal Exchange plans to end trading of gold and silver futures by July, citing low levels of trading activity, according to reports on Friday. The LMEprecious service, an initiative created by the LME, the World Gold Council and a group of leading industry players to introduce exchange-traded London precious metals products, is expected […]

Apr 22
Biogen stock slides 2% after it withdraws authorization application with EU regulator

Biogen Inc. shares BIIB, -3.21% fell 2% Friday, after the company said it has withdrawn the marketing authorization application for its controversial Alzheimer’s treatment aducanumab with the European regulator because early communications suggest the data is not sufficient to gain a positive opinion. “We stand by the safety and efficacy of aducanumab, and we look […]